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Abstract
The NRF2 signalling cascade provides a primary response against electrophilic
chemicals and oxidative stress. The activation of NRF2-signaling is anticipated to
have adverse clinical consequences; NRF2 is activated in a number of cancers
and, additionally, its pharmacological activation by one compound can reduce the
toxicity or efficiency of a second agent administered concomitantly. In this work, we
have analysed systematically the ability of 152 research, pre-clinical or clinically
used drugs to induce an NRF2 response using the MCF7-AREc32 NRF2 reporter.
Ten percent of the tested drugs induced an NRF2 response. The NRF2 activators
were not restricted to classical cytotoxic alkylating agents but also included a
number of emerging anticancer drugs, including an IGF1-R inhibitor (NVP-
AEW541), a PIM-1 kinase inhibitor (Pim1 inhibitor 2), a PLK1 inhibitor (BI 2536) and
most strikingly seven of nine tested HDAC inhibitors. These findings were further
confirmed by demonstrating NRF2-dependent induction of endogenous AKR
genes, biomarkers of NRF2 activity. The ability of HDAC inhibitors to stimulate
NRF2-signalling did not diminish their own potency as antitumour agents. However,
when used to pre-treat cells, they did reduce the efficacy of acrolein. Taken
together, our data suggest that the ability of drugs to stimulate NRF2 activity is
common and should be investigated as part of the drug-development process.
Introduction
NF-E2 p45-related factor 2 (Nrf2), a cap ‘n’ collar (CNC) basic-region leucine
zipper (bZIP) transcription factor regulates a transcriptional programme that
enables cells to withstand transient periods of exposure to stress [1]. This
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evolutionarily-conserved transcriptional programme involves the binding of
NRF2 to the Antioxidant Response Element (ARE), a DNA element found in the
promoters of numerous genes involved in drug detoxication (glutathione S-
transferases, aldo-keto reductases), drug transport and anti-oxidant defense, such
as haem oxygenase 1, malic enzyme, thioredoxin and glucose 6-phosphate
dehydrogenase. Moreover, NRF2 can enhance the activity of key pathways
involved in maintaining proteostasis, including the 26S proteasome and
autophagy [2]. These adaptations and others collectively confer a survival
phenotype upon cells that minimises damage to their functional and structural
integrity.
Under normal metabolic conditions, NRF2 activity is restrained by the
CRL3KEAP1/KEAP1 ubiquitin ligase complex [3]. Kelch-like ECH-associated Protein
1 (KEAP1) provides a substrate recognition signal for the Cullin-3-Rbx1 Ligase
(CRL3) holoenzyme leading to the transcription factor’s rapid ubiquitylation and
degradation. Normally, it is only in stressed cells that NRF2 transiently
accumulates and initiates an adaptive response. This accumulation results from
the inactivation of KEAP1 by ‘danger’ signals, such as zinc or lipid peroxidation
products, or toxic electrophiles [4].
The activation of the NRF2 signalling cascade is an adaptive response which
generates resistance to further cytotoxic stress, resulting in cell survival [5]. While
transient activation of NRF2 in normal cells is desirable, persistent activation of
NRF2 is deleterious [6]. For example, in the setting of cancer, recurrent mutations
in KEAP1 and NRF2 resulting in its constitutive activation have been observed in
up to 34% of lung tumours [7–9] and also in several other types of tumours,
including head-and-neck, skin, prostate, and pancreatic cancers [7, 10].
Constitutive NRF2 signalling is believed to benefit the neoplastic cells (and is thus
detrimental to the host organism) because it facilitates cell proliferation (10).
Also, NRF2 activation will boost cell survival and prevent apoptosis [12]. For
similar reasons, it may also play a role in chemo-resistance [2]. Related to these
effects, mutations in KEAP1 and NRF2 are associated with a poor prognosis in
lung cancer patients [11]. Uncontrolled activation of NRF2 might also be harmful
in the context of normal cells as genetic or pharmacological activation of NRF2
causes epidermal thickening and hyperkeratosis in mice that resemble the human
disease lamellar ichythosis [13].
These examples – and the fact that NRF2 activity is so tightly controlled –
suggest that opportunistic stimulation of NRF2 signalling by drugs used in the
treatment of cancer is undesirable. Not only will it potentially contribute to the
survival and proliferation of pre-malignant cells, it may also give rise to
unexpected drug-drug interactions as a consequence of NRF2’s ability to induce
drug detoxication genes. In this study, we set out to examine systematically the
frequency with which clinical drugs or drugs in development can activate NRF2
signalling. Our data suggest that this ability is a common feature of a small but
significant fraction of therapeutic agents – including in particular histone
deacetylase (HDAC) inhibitors.
Anticancer Drugs Exacerbate NRF2 Signaling
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Materials and Methods
Cell line
The MCF7-AREc32 cell line was derived in the authors’ laboratory and has been
previously described [14]. The growth medium was DMEM with glutamax,
supplemented with 10% (v/v) fetal bovine serum, 1x penicillin-streptomycin
supplement, and 0.8 mg/ml G418. A-431 (ATCC CRL-1555) cells were obtained
from ATCC and cultured in DMEM with glutamax, supplemented with 10% (v/v)
fetal bovine serum, 1x penicillin-streptomycin. Cells were maintained at 37 C˚ in a
humidified atmosphere containing 5% CO2.
Chemicals
Chemicals were from commercial suppliers or academic collaborators. We
provide a full description of each chemical, including name, source, putative
therapeutic target and screening clinical status in Table S1. Compounds were
dissolved in dimethyl sulfoxide at a final concentration of 10 mM (or at
maximum solubility), and stored at 220 C˚.
Luciferase activity assay
Luciferase activity was measured using the Luciferase Assay System (Promega),
according to the manufacturer’s instructions. Briefly, cells in each well of a 96-well
plate were washed with PBS and lysed in 30 ml of the lysis buffer provided with the
kit. A 5 ml portion of the lysate was mixed with 25 ml of Luciferase assay reagent
and the luminescence was quantified using the Orion II Microplate Luminometer
(Berthold Detection Systems).
Cell viability assay
The Adenosine 59-triphosphate (ATP) bioluminescent somatic cell assay kit
(Sigma-Aldrich) was used to determine cell viability, as described by the
manufacturer. Briefly, cells in each well of a 96-well plate were lysed in 45 ml of the
Somatic Cell ATP Releasing Reagent. Of this volume of lysate, 30 ml was
transferred to a white-walled 96-well plate. To this was added 30 ml of
resuspended Adenosine 59triphosphate (ATP) Assay Mix and the resulting
luminescence measured using the Orion II Microplate Luminometer (Berthold
Detection Systems). To calculate Relative IC50 values, the resulting data were fitted
to a Sigmoidal Dose-Response Curve (variable slope), as implemented in
GraphPad Prism. The TOP parameter was fixed at 100% cell viability.
Screen of MCF7-AREc32 cell line
The screen was performed in two stages. An initial primary screen was performed
during which MCF7-AREc32 cells were seeded into 96-well plates at 5000 cells/
well. After 24 h, single wells of cells were exposed to a 7-point ten-fold serial
Anticancer Drugs Exacerbate NRF2 Signaling
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dilution series of each compound starting at 50 mM. After a further 24 h had
elapsed, the luciferase activity and cell viability in control and treated cells was
determined. Only those chemicals that displayed at least a two-fold increase in
Luciferase activity at minimally one dose were taken forward into the secondary
screen. For the secondary screen, the MCF7-AREc32 cells were plated as for the
primary screen. They were treated in triplicate with an 11-point, four-fold
dilution series of each test compound. Luciferase activity, and, using a separate set
of plates, cell viability, was assayed at the 24 h time point. For each chemical, we
determined the fold-change in Luciferase activity compared with control wells (x
¡ S.E.M, n53). Compounds that caused a fold increase in Luciferase activity that
was significantly greater than two (x –2*S.E.M.2) while causing no greater than a
20% decline in cell viability were considered to stimulate NRF2 activity.
Immunoblots
Whole-cell lysates were prepared by scraping cells into ice-cold radioimmune
precipitation assay buffer (50 mM Tris-Cl, pH 7.4, 150 mM NaCl, 1% (v/v)
Nonidet P-40, 0.5% (w/v) deoxycholic acid, 0.1% (w/v) SDS). Lysates were
clarified by centrifugation (16,000 6 g, 15 min, 4 C˚). Protein determination,
SDS/polyacrylamide-gel electrophoresis and immunoblotting were carried out as
previously described [15]. Antibodies used included rabbit sera raised against
AKR1B10 [16], AKR1C1 [17], NRF2 [18] a mouse monoclonal antibody raised
against AKR1C3 (gift from Prof. Trevor Penning, University of Pennsylvania) and
a mouse anti-GAPDH antibody, clone GAPDH_71.1 (Sigma).
Relative quantification of mRNA species
This was carried out by TaqMan chemistry. Total RNA was isolated from MCF7-
AREc32 cells using Ambion RNA Extraction Kit (Ambion) followed by DNase
treatment (RQ1 RNase-free DNase, Promega). Approximately 0.4 mg of total
RNA was reverse-transcribed to cDNA using random hexamers (Promega) and
the ImProm II Reverse Transcription System (Promega) according to the
manufacturer’s instructions. The PCR mixes were prepared by mixing 6 ml of
cDNA (diluted 1:40) with 0.75 ml of TaqMan probe set and 7.5 ml of Master Mix
(PerkinElmer Applied Biosystems). For the real-time PCR analysis, the following
pre-designed TaqMan probe sets in solution were used: AKR1C1: Hs00413886;
Luciferase: Mr03987587; 18 s ribosomal RNA: Hs03003631 (all from PerkinElmer
Applied Biosystems). Data acquisition and analysis utilised the ABI PRISM 7700
sequence detection system (PerkinElmer Applied Biosystems). The relative gene
expression levels in different samples were calculated using the Comparative CT
Method as outlined in the ABI PRISM 7700 Sequence Detection System User
Bulletin #2. The expression of 18 s rRNA was used as the internal control.
Anticancer Drugs Exacerbate NRF2 Signaling
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NRF2 knock-down
1.56106 MCF7-AREc32 cells were reverse transfected in 100-mm Tissue Culture
dishes with 40 ml LipofectAMINE RNAiMAX (Invitrogen) and 250 pmoles of
siRNA. The siRNAs that were used were ON-TARGETplus Non-targeting siRNA
#4 (Dharmacon) and ON-TARGET plus SMARTpool human NFE2L2
(Dharmacon).
Results
Drug-induced NRF2-ARE signalling
As previously described, the MCF7-AREc32 cell line contains low levels of NRF2
and, therefore, low levels of luciferase expression [14]. This makes it an excellent
cell model with which to identify drugs that activate NRF2 signalling. We
assembled a library of 152 drugs which target a variety of biochemical pathways
(Table S1); the selection of compounds, however, was made with no fore-
knowledge or preconception of their likelihood to stimulate NRF2 signalling. An
initial primary screen using this library identified 46 candidate chemicals that
elevated luciferase activity in the MCF7-AREc32 cell line (Table S1). The more
extensive secondary 11-point cytotoxicity screen confirmed that thirteen of these
compounds induced ARE-driven luciferase expression (Figs. S1 & S2 and Fig. 1).
Surprisingly, only three of the thirteen activators (carmustine, lomustine,
melphalan) are conventional cytotoxic drugs. The remainder of the active
compounds were newer targeted therapies and they included a PLK1 inhibitor (BI
2536), a PIM-1 kinase inhibitor (Pim-1 inhibitor 2), and an IGF-1R inhibitor
(NVP-AEW541). Most strikingly, however, we observed that seven of nine tested
HDAC inhibitors (belinostat (Bel), CHR-3531, CI-994, entinostat (Ent),
panobinostat (Pan), trichostatin A (Tri) and vorinostat (Vor)) increased
Luciferase activity. Besides these thirteen activators, our screen identified two
inhibitors of NRF2-ARE signalling: Epirubicin, a DNA-intercalating agent, and
Bexarotene, an RXR agonist (Fig. S3). Collectively, these data showed that
approximately 10% of the compounds tested altered NRF2-ARE signalling.
PIM-1 kinase and IGF-1R inhibitors induced ARE activity
We confirmed by TaqMan mRNA analysis and Western-blot analysis that Pim1
inhibitor 2 and NVP-AEW541 stimulated expression not only of the luciferase
reporter but also of previously authenticated NRF2-target genes. For example,
both compounds increased the steady-state level of various members of the Aldo-
Keto Reductase (AKR) family of proteins [16] (Fig. 2A & B). Moreover, we
successfully knocked-down NRF2 mRNA (Fig. S4A) and protein (Fig. S4B) using
RNAi; this approach was used to reveal that the enhanced AKR expression in
response to both Pim1 inhibitor 2 and NVP-AEW541 was mediated at least in
part via NRF2 signalling (Fig. 2C). Sulforaphane (SFN), the prototypic NRF2
inducer, was included in these experiments as a positive control [19]. As expected,
Anticancer Drugs Exacerbate NRF2 Signaling
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Figure 1. HDAC inhibitors stimulate ARE activity. Cell viability and luciferase activities were measured in separate plates of MCF7-AREc32 cells exposed
to the indicated doses of the noted HDAC inhibitors for 24 h. Each measured parameter is plotted as x ¡S.E.M of three independent experiments.
doi:10.1371/journal.pone.0114055.g001
Anticancer Drugs Exacerbate NRF2 Signaling
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the ability of SFN to boost AKR expression showed absolute dependency on
NRF2; this result suggests that both NVP-AEW541 and Pim1 inhibitor 2 may
additionally influence AKR expression by means other than NRF2 (Fig. 2C).
Finally, we found that the cytotoxicity of NVP-AEW541 (but not Pim1 inhibitor
2) was modestly impaired by NRF2 signalling, as knock-down of NRF2
significantly (P,0.05, compared with non-template control cells) reduced the
chemical’s Relative IC50 value in this cell line (Fig. 2D).
Figure 2. Pim 1 inhibitor II and NVP-AEW increase ARE activity. A & B, MCF7-AREc32 cells were exposed to the indicated doses of Pim1 inhibitor 2
(Pim1), NVP-AEW541 or SFN. After 24 h had elapsed, total RNA was prepared, reverse-transcribed to cDNA and levels of AKR1C1 and luciferase mRNA
was measured by real-time PCR (A). Alternatively, whole-cell lysates were prepared from duplicate dishes of cells and blotted for the indicated proteins (B).
GAPDH serves as a loading control. C, MCF7-AREc32 cells were treated with non-targeting (siNT) or NRF2 targeting (siNRF2) siRNAs and, 48 h later, they
were exposed to different doses of the indicated chemicals. After 24 h had elapsed, mRNA was prepared, and the amount of AKR1C1mRNA determined by
real-time quantitative PCR D, MCF7-AREc32 cells were treated with non-targeting (siNT) or NRF2 targeting (siNRF2) siRNAs and, 48 h later, they were
exposed to different doses of the indicated chemicals. Cell viability was assessed 72 h later. Data are presented as x ¡S.E.M of three independent
experiments.
doi:10.1371/journal.pone.0114055.g002
Anticancer Drugs Exacerbate NRF2 Signaling
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HDAC inhibitors increase expression of ARE-activated genes
Quantitative RT-PCR confirmed that six of seven separate HDAC inhibitors
upregulated mRNA encoding not only luciferase but also the endogenous NRF2-
regulated AKR1C1 gene (Fig. 3A – G). The exception was Pan (Fig. 3E). In
general, these drugs had a considerably more profound effect on luciferase
expression than on AKR1C1 expression. Vor was an outlier to this trend; it
displayed more pronounced activation of AKR1C1 than it did luciferase (Fig. 3G).
Upregulation of AKR1C1 mRNA was paralleled by an increase in the
corresponding protein (Fig. 4).
CI-994 and Ent consistently increased the expression of AKR1C1 protein to a
greater extent than the other four remaining HDAC inhibitors in MCF7-AREc32
cells. Moreover, this activity is not peculiar to this cell line as both compounds
also elevated AKR protein amounts in the epidermoid carcinoma A-431 cell line
(Fig. 5A). For this reason, we restricted subsequent more in-depth analyses to
these two compounds. We first confirmed by NRF2 knock-down (Fig. 5A) that
these chemicals increase the expression of AKR mRNA (Fig. 5C & D) and protein
(Fig. 5E & F) levels via this transcription factor in MCF7-AREc32 cells. Notably,
however, these experiments also revealed that Ent and CI-994 were both less
reliant upon NRF2 for augmentation of AKR expression than SFN. In a similar
vein, we also noticed that expression of the luciferase reporter in response to Ent
and CI-994– but not SFN – was largely independent of NRF2, in contrast to the
endogenous AKR genes (c.f. Fig. 5B with Fig. 5C & D). Indeed, Ent displayed no
dependence upon NRF2 in this experimental setting.
HDAC inhibitor cytotoxicity is NRF2-independent
In the light of the finding that HDAC inhibitors increased NRF2 signalling and
the expression of downstream genes, we tested whether NRF2 signalling affected
the cytotoxicity of these compounds as single-use agents. In the first instance, we
knocked-down NRF2 expression. At 48 h, at which point AKR expression is
already significantly reduced, we exposed control or NRF2 knock-down cells to
the various HDAC inhibitors. Cytotoxicity was assessed 72 h later. The data
showed that the potency of these seven agents in this cell line is unaffected by
inhibiting NRF2 signalling (Fig. 6). Secondly, we examined whether increasing
NRF2 activity prior to exposure of cells to HDAC inhibitors might affect HDAC
inhibitor efficacy. In these experiments, we primed cells with a low dose of SFN
for 24 h before exposing the cells to the HDAC inhibitors. Again, no difference in
Ent or CI-994 cytotoxicity was observed between the primed and the control cells
(Fig. 7).
Exposure of cells to HDAC inhibitors reduces the cytotoxicity of
acrolein
Although the cytotoxicities of the HDAC inhibitors themselves were not altered
by diminishing or augmenting NRF2 signalling (Figs. 6 & 7), we investigated
Anticancer Drugs Exacerbate NRF2 Signaling
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whether the ability of this class of inhibitors to activate NRF2 might blunt the
toxicity of co-administered drugs. As a proof-of-principle, we examined acrolein
(Acro), a lipid peroxide break-down product and a cytotoxic metabolite of
cyclophosphamide. In agreement with earlier work [20], priming cells with SFN
blunted the cytotoxicity of Acro (Fig. 8). Additionally, pre-treatment of cells with
CI-994 increased the Relative IC50 value for Acro significantly (P,0.05 at both
Figure 3. HDAC inhibitors increase expression of AKR1C1 mRNA. A – G, MCF7-AREc32 cells were
cultured for 24 h in the presence of the indicated concentrations of the stated HDAC inhibitors. The
expression levels of AKR1C1 and LuciferasemRNAs (relative to vehicle control) was determined by real-time
quantitative PCR. Data are plotted as x ¡S.E.M of three independent experiments.
doi:10.1371/journal.pone.0114055.g003
Anticancer Drugs Exacerbate NRF2 Signaling
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doses compared to control). For example, the Relative IC50 value for Acro in
control cells was 36 mM versus 50 mM in cells pretreated with 50 mM CI-994. Ent
also appeared to mitigate the cytotoxicity of Acro (Relative IC50 in control cells of
40 mM versus 65 mM in cells pre-treated with 2.5 mM Ent) but the effect was not
statistically significant (Fig. 8). Finally, we confirmed that chemoprotection by CI-
994 was partly NRF2-dependent by demonstrating that knock-down of the
transcription factor exacerbated Acro toxicity in both control cells and cells pre-
treated with CI-994 (P,0.05 in both populations). Unsurprisingly, CI-994 still
offers some residual protection to NRF2 kd cells, consistent with our finding that
it augments AKR protein levels to some extent even in the absence of the
transcription factor (Fig. 5).
Discussion
We have found that approximately 10% of a randomly chosen collection of largely
clinical or pre-clinical drugs alter NRF2 signaling in the MCF7-AREc32 reporter
cell line. These included the classic cytotoxic agents carmustine, lomustine,
melphalan, in addition to the DNA intercalating agent epirubicin. Surprisingly,
however, many of these drugs are targeted agents that lack the reactive moieties
that might be expected to disrupt the NRF2-KEAP1 negative-feedback loop
directly and, thus, stimulate NRF2 activity. These targeted drugs included an RXR
agonist (bexarotene), an IGF1-R inhibitor (NVP-AEW541), a PIM-1 kinase
Figure 4. HDAC inhibitors increase expression of a range of AKR proteins. MCF7-AREc32 cells were
treated with the stated concentration of chemicals for 24 h. Whole-cell lysates were prepared and blotted for
the indicated proteins.
doi:10.1371/journal.pone.0114055.g004
Anticancer Drugs Exacerbate NRF2 Signaling
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inhibitor (Pim1 inhibitor 2), a PLK1 inhibitor (BI 2536) and – most strikingly –
seven of nine tested HDAC inhibitors. These effects may be either indirect or due
to the modulation of pathways directly involved in the regulation of NRF2
function.
For certain of the drugs tested, there is a mechanistic rationale why they
influence NRF2 signalling. In the case of bexarotene, an RXR agonist, for example,
the finding that this compound reduced NRF2 signaling (Fig. S3) is consistent
with our earlier finding that RXR acts as a negative regulator of NRF2-ARE
signalling [21]. This provides further evidence supporting the interaction. In other
cases, it is more likely that the effects are indirect. For example, we found the IGF-
Figure 5. HDAC inhibitors increase ARE-driven gene expression in part via NRF2. A, Duplicate dishes of A-431 cells were treated with CI-994, Ent or
vehicle control for 24 h and blotted for the indicated proteins. B – F, MCF7-AREc32 cells were treated with non-targeting (siNT) or NRF2 targeting (siNRF2)
siRNAs and, 48 h later, they were exposed to different doses of the indicated chemicals for 24 h. The expression level of Luciferase (B), AKR1C1 (C) or
AKR1C3 (D) was determined by real-time quantitative PCR. Protein levels (E & F) were determined by immunoblot. Data are presented as x ¡S.E.M of
three independent experiments (B – D).
doi:10.1371/journal.pone.0114055.g005
Anticancer Drugs Exacerbate NRF2 Signaling
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1R inhibitor NVP-AEW541 stimulated NRF2 signalling, whereas a previous study
reported that IGF-1 deficiency in vivo decreased NRF2 activity [22]. This
difference could be explained if NVP-AEW541 has off-target effects. This is
supported by the observation that the effects of NVP-AEW541 on ARE-driven
gene expression were only partially NRF2-dependent (Fig. 2C).
Figure 6. HDAC cytotoxicity is unaffected by NRF2 knock-down. MCF7-AREc32 cells were treated with
non-targeting (siNT) or NRF2 targeting (siNRF2) siRNAs and, 48 h later, they were exposed to different doses
of the indicated chemicals. Cell viability was assessed 72 h later. Data are presented as x ¡S.E.M of three
independent experiments.
doi:10.1371/journal.pone.0114055.g006
Anticancer Drugs Exacerbate NRF2 Signaling
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Figure 7. HDAC cytotoxicity is not diminished by prior activation of NRF2. MCF7-AREc32 cells were treated with 5 mM SFN or vehicle (DMSO). After
24 h had elapsed, they were exposed to various concentrations of CI-994 or Ent. Cell viability was assessed 72 h later. Data are presented as x¡S.E.M of
three independent experiments.
doi:10.1371/journal.pone.0114055.g007
Figure 8. Pre-treatment with HDAC inhibitor CI-994 reduces the cytotoxicity of acrolein. A & B, MCF7-AREc32 cells were pre-treated with 5 mM SFN,
the indicated doses of CI-994 and Ent, or vehicle (DMSO). After 24 h had elapsed, they were exposed to various concentrations of Acro. Cell viability was
assessed 72 h later. Data are presented as x¡S.E.M of three independent experiments. C, MCF7-AREc32 cells were treated with non-targeting (siNT) or
NRF2 targeting (siNRF2) siRNAs. The following day, they were pre-treated with 50 mM CI-994 or vehicle (DMSO). After 24 h of pre-treatment, cells were
washed and exposed to different Acro. Cell viability was assessed 72 h later. Data are presented as x ¡S.E.M of three independent experiments.
doi:10.1371/journal.pone.0114055.g008
Anticancer Drugs Exacerbate NRF2 Signaling
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The ability of HDAC inhibitors to activate NRF2 signalling was particularly
striking. The fact that multiple, structurally dissimilar, HDAC inhibitors were
identified in our screen suggests that this represents an on-target effect. NRF2 is
known to be acetylated in a manner which influences its activity [23]. The other
alternative is that HDAC inhibitors exert their effects by affecting chromatin
organisation at NRF2-target genes. Two observations suggest that modifications
to chromatin structure are important. Firstly, CI-994 and Ent had more profound
effects upon expression of AKR genes than did the remaining HDAC inhibitors;
these two inhibitors are differentiated from the others by their specificity [24].
They primarily target HDAC I and III proteins that specifically deacetylate
histones. The remaining inhibitors are less specific and also inhibit HDACs that
deacetylate non-histone proteins. Secondly, we consistently noted that HDAC
inhibitors retained some ability to induce AKR genes even when NRF2 expression
was suppressed. This can be rationalised if these inhibitors open up the chromatin
structure and, thus, reduce the stringency of the requirement for NRF2 to
stimulate AKR gene expression.
Our primary aim in performing this work was to examine whether drugs might
disturb NRF2 signalling. Unanticipated NRF2 stimulation is clinically undesirable,
having potentially deleterious consequences for drug efficacy and patient
outcome. For example, NRF2 is a proto-oncogene and, therefore, drugs that
inadvertently stimulate its activity might promote the survival of pre-existing pre-
malignant cells [25]. For example, NRF2 activity promoted tumourigenesis in a
genetically-engineered mouse model of pancreatic cancer, at least in part by
mitigating oncogene-driven ROS formation [12]. Failure to control ROS also
accounts for the finding that lack of NRF2 reduced tumour aggressiveness and
increased survival in a BrafV600E-driven mouse model of lung cancer [26]. In
addition to counteracting ROS, NRF2 may also support tumour formation by
redirecting glucose and glutamine into anabolic pathways [11]. Finally, NRF2
signalling is undesirable because it drives a transcriptional response that confers a
chemo-resistant phenotype on cells. By boosting chemo-resistance of tumours,
targeted drugs that augment NRF2 activity might impair the cytotoxicity of co-
administered cytotoxic agents to the detriment of patients. This is particularly the
case as there is increasing interest in the use of targeted drugs, such as HDAC
inhibitors, in combination with standard chemotherapies [24]. The potential for
adverse drug-drug interactions between HDAC inhibitors and co-administered
cytotoxic chemicals is exemplified by our observation that pre-treatment of
MCF7-AREc32 cells with CI-994 impaired the cytotoxic effects of Acro, a reactive
chemical and cyclophosphamide breakdown product. Although the magnitude of
the drug-drug interaction observed between CI-994 and Acro was modest, many
cytotoxic drugs have very narrow therapeutic windows and even a 50% increase in
Relative IC50 values, such as observed here, might have adverse clinical
consequences [27]. In addition, the efficacy of at least some stand-alone agents
might be reduced by their own ability to stimulate NRF2 signaling. This is
suggested by the observation that the cytotoxicity of NVP-AEW541 in MCF7-
AREc32 cells is exacerbated by knocking-down NRF2 levels (Fig. 2D).
Anticancer Drugs Exacerbate NRF2 Signaling
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In summary, many anti-tumour agents have the unanticipated ability to
stimulate NRF2 signaling. As a consequence, the effectiveness of certain therapies
could be attenuated. It would therefore be appropriate to test for such effects as
part of the drug development process.
Supporting Information
Figure S1. Chemotherapeutic alkylating agents stimulate NRF2 activity. Cell
viability and luciferase activities were measured in separate plates of MCF7-
AREc32 cells exposed to the indicated doses of the specified alkylating agents.
Each measured parameter is plotted as x ¡S.E.M of three independent
experiments.
doi:10.1371/journal.pone.0114055.s001 (TIF)
Figure S2. Stimulation of NRF2 activity by an IGF1-R inhibitor and a PIM-1
Kinase inhibitor. Cell viability and luciferase activities were measured in
separate plates of MCF7-AREc32 cells exposed to the indicated doses of NVP-
AEW541 or Pim1 Inhibitor 2. Each measured parameter is plotted as x¡S.E.M
of three independent experiments.
doi:10.1371/journal.pone.0114055.s002 (TIF)
Figure S3. Epirubicin (Epi) and bexarotene (Bex) inhibit NRF2 activity. Cell
viability and luciferase activities were measured in separate plates of MCF7-
AREc32 cells exposed to the indicated doses of Epi or Bex. Each measured
parameter is plotted as x ¡S.E.M of three independent experiments.
doi:10.1371/journal.pone.0114055.s003 (TIF)
Figure S4. NRF2 knock-down in MCF7-AREc32 cells. MCF7-AREc32 cells were
treated with non-targeting (siNT) or NRF2 targeting (siNRF2) siRNAs. After 72 h
had elapsed, total RNA was prepared, and the amount of NRF2 mRNA
determined by real-time quantitative PCR (A). Alternatively, cells were treated
with SFN or vehicle (DMSO) for a further 2 h before preparing cell lysates and
blotting for the indicated proteins (B). The band representing NRF2 is indicated
with an asterisk.
doi:10.1371/journal.pone.0114055.s004 (TIF)
Table S1. Chemicals screened during this study. This table contains a complete
list of the chemicals screened in the MCF7-AREc32 cell line during this study.
The table also includes other relevant information regarding the compounds,
including their supplier, presumed biological target, and clinical status.
doi:10.1371/journal.pone.0114055.s005 (XLSX)
Author Contributions
Conceived and designed the experiments: MM CJH CRW. Performed the
experiments: KHC AKM LAM. Analyzed the data: MM KHC AKM LAM. Wrote
the paper: MM CRW.
Anticancer Drugs Exacerbate NRF2 Signaling
PLOS ONE | DOI:10.1371/journal.pone.0114055 November 26, 2014 15 / 17
References
1. Taguchi K, Motohashi H, Yamamoto M (2011) Molecular mechanisms of the Keap1–Nrf2 pathway in
stress response and cancer evolution. Genes Cells 16: 123–140. Available: http://www.ncbi.nlm.nih.gov/
pubmed/21251164. Accessed 31 March 2014.
2. Hayes JD, McMahon M (2009) NRF2 and KEAP1 mutations: permanent activation of an adaptive
response in cancer. Trends Biochem Sci 34: 176–188. Available: ,Go to ISI.://000265757600005.
3. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, et al. (2004) Oxidative stress sensor Keap1
functions as an adaptor for Cul3-based E3 ligase to regulate for proteasomal degradation of Nrf2. Mol
Cell Biol 24: 7130–7139. Available: ,Go to ISI.://000223045600022.
4. McMahon M, Lamont DJ, Beattie KA, Hayes JD (2010) Keap1 perceives stress via three sensors for
the endogenous signaling molecules nitric oxide, zinc, and alkenals. Proc Natl Acad Sci U S A 107:
18838–18843. Available: http://www.pubmedcentral.nih.gov/articlerender.
fcgi?artid52973898&tool5pmcentrez&rendertype5abstract. Accessed 2 November 2010.
5. Wolf CR (2001) Chemoprevention: increased potential to bear fruit. Proc Natl Acad Sci U S A 98: 2941–
2943. Available: http://www.pubmedcentral.nih.gov/articlerender.
fcgi?artid533333&tool5pmcentrez&rendertype5abstract.
6. Sporn M, Liby K (2012) NRF2 and cancer: the good, the bad and the importance of context. Nat Rev
Cancer 3: 1–8. Available: http://dx.doi.org/10.1038/nrc3278. Accessed 3 October 2012.
7. Slocum SL, Kensler TW (2011) Nrf2: control of sensitivity to carcinogens. Arch Toxicol 85: 273–284.
Available: http://www.ncbi.nlm.nih.gov/pubmed/21369766. Accessed 3 April 2011.
8. Hammerman PS, Lawrence MS, Voet D, Jing R, Cibulskis K, et al. (2012) Comprehensive genomic
characterization of squamous cell lung cancers. Nature 489: 519–525. Available: http://www.nature.com/
doifinder/10.1038/nature11404. Accessed 9 September 2012.
9. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, et al. (2012) Mapping the
Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing. Cell 150: 1107–1120.
Available: http://linkinghub.elsevier.com/retrieve/pii/S0092867412010616. Accessed 13 September
2012.
10. Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, et al. (2008) Genetic alteration of Keap1 confers
constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 135:
1358–1368. Available: ,Go to ISI.://000259982800043.
11. Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, et al. (2012) Article Nrf2 Redirects Glucose
and Glutamine into Anabolic Pathways in Metabolic Reprogramming. Cancer Cell 22: 66–79. Available:
http://dx.doi.org/10.1016/j.ccr.2012.05.016.
12. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, et al. (2011) Oncogene-induced Nrf2
transcription promotes ROS detoxification and tumorigenesis. Nature 475: 106–109. Available: http://dx.
doi.org/10.1038/nature10189. Accessed 31 March 2014.
13. Scha M, Farwanah H, Willrodt A, Huebner AJ, Sandhoff K, et al. (2012) Nrf2 links epidermal barrier
function with antioxidant defense. EMBO Mol Med 4: 364–379. doi:10.1002/emmm.201200219.
14. Wang XJ, Hayes JD, Wolf CR (2006) Generation of a stable antioxidant response element-driven
reporter gene cell line and its use to show redox-dependent activation of nrf2 by cancer
chemotherapeutic agents. Cancer Res 66: 10983–10994. Available: http://www.ncbi.nlm.nih.gov/
pubmed/17108137. Accessed 8 August 2012.
15. McMahon M, Itoh K, Yamamoto M, Hayes JD (2003) Keap1-dependent proteasomal degradation of
transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven
gene expression. J Biol Chem 278: 21592–21600. Available: http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd5Retrieve&db5PubMed&dopt5Citation&list_uids512682069.
16. MacLeod a K, McMahon M, Plummer SM, Higgins LG, Penning TM, et al. (2009) Characterization of
the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that
the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against
electrophiles as well as redox-cycling compounds. Carcinogenesis 30: 1571–1580. Available: http://
www.ncbi.nlm.nih.gov/pubmed/19608619. Accessed 26 October 2012.
Anticancer Drugs Exacerbate NRF2 Signaling
PLOS ONE | DOI:10.1371/journal.pone.0114055 November 26, 2014 16 / 17
17. Connor TO, Ireland LS, Harrison DJ, Hayes JD (1999) Major differences exist in the function and
tissue-specific expression of humn aldo-keto reductase AKR1 family members. Biochem J 504: 487–
504.
18. McMahon M, Thomas N, Itoh K, Yamamoto M, John D, et al. (2006) Dimerization of substrate
adaptors can facilitate cullin-mediated ubiquitylation of proteins by a ‘‘Tethering’’ mechanism - A two-site
interaction model for the Nrf2-Keap1 complex. J Biol Chem 281: 24756–24768. Available: http://www.
ncbi.nlm.nih.gov/pubmed/16790436. Accessed 12 April 2013.
19. Gao X, Dinkova-Kostova a T, Talalay P (2001) Powerful and prolonged protection of human retinal
pigment epithelial cells, keratinocytes, and mouse leukemia cells against oxidative damage: the indirect
antioxidant effects of sulforaphane. Proc Natl Acad Sci U S A 98: 15221–15226. Available: http://www.
pubmedcentral.nih.gov/articlerender.fcgi?artid565010&tool5pmcentrez&rendertype5abstract.
20. Higgins LG, Kelleher MO, Eggleston IM, Itoh K, Yamamoto M, et al. (2009) Transcription factor Nrf2
mediates an adaptive response to sulforaphane that protects fibroblasts in vitro against the cytotoxic
effects of electrophiles, peroxides and redox-cycling agents. Toxicol Appl Pharmacol 237: 267–280.
Available: http://www.ncbi.nlm.nih.gov/pubmed/19303893. Accessed 31 October 2012.
21. Wang XJ, Hayes JD, Henderson CJ, Wolf CR (2007) Identification of retinoic acid as an inhibitor of
transcription factor Nrf2 through activation of retinoic acid receptor alpha. Proc Natl Acad Sci U S A 104:
19589–19594. Available: http://www.pubmedcentral.nih.gov/articlerender.
fcgi?artid52148333&tool5pmcentrez&rendertype5abstract.
22. Bailey-downs LC, Mitschelen M, Sosnowska D, Toth P, Pinto JT, et al. (2012) Liver-specific
knockdown of IGF-1 decreases vascular oxidative stress resistance by impairing the Nrf2-dependent
antioxidant response: a novel model of vascular aging. J Gerontol A Biol Sci Med Sci 67: 313–329.
Available: http://www.pubmedcentral.nih.gov/articlerender.
fcgi?artid53309870&tool5pmcentrez&rendertype5abstract. Accessed 17 May 2013.
23. Sun Z, Chin YE, Zhang DD (2009) Acetylation of Nrf2 by p300/CBP augments promoter-specific DNA
binding of Nrf2 during the antioxidant response. Mol Cell Biol 29: 2658–2672. Available: http://www.
pubmedcentral.nih.gov/articlerender.fcgi?artid52682049&tool5pmcentrez&rendertype5abstract.
Accessed 26 April 2013.
24. Frew AJ, Johnstone RW, Bolden JE (2009) Enhancing the apoptotic and therapeutic effects of HDAC
inhibitors. Cancer Lett 280: 125–133. Available: http://www.ncbi.nlm.nih.gov/pubmed/19359091.
Accessed 12 March 2013.
25. Suzuki T, Motohashi H, Yamamoto M (2013) Toward clinical application of the Keap1–Nrf2 pathway.
Trends Pharmacol Sci:1–7. Available: http://linkinghub.elsevier.com/retrieve/pii/S0165614713000667.
Accessed 14 May 2013.
26. Strohecker AM, Guo JY, Karsli-Uzunbas G, Price SM, Chen GJ, et al. (2013) Autophagy Sustains
Mitochondrial Glutamine Metabolism and Growth of BrafV600E-Driven Lung Tumors. Cancer Discov 3:
1272–1285. Available: http://www.ncbi.nlm.nih.gov/pubmed/23965987. Accessed 13 December 2013.
27. Mathijssen RHJ, Sparreboom A, Verweij J (2014) Determining the optimal dose in the development of
anticancer agents. Nat Rev Clin Oncol Available: http://www.ncbi.nlm.nih.gov/pubmed/24663127.
Accessed 26 March 2014.
Anticancer Drugs Exacerbate NRF2 Signaling
PLOS ONE | DOI:10.1371/journal.pone.0114055 November 26, 2014 17 / 17
